Orchid Pharma Limited (BOM:524372)
India
· Delayed Price · Currency is INR 810.85
+0.85 (0.10%)
At close: Apr 23, 2025
Orchid Pharma Statistics
Total Valuation
Orchid Pharma has a market cap or net worth of INR 41.14 billion. The enterprise value is 40.35 billion.
| Market Cap | 41.14B |
| Enterprise Value | 40.35B |
Important Dates
The next estimated earnings date is Friday, May 30, 2025.
| Earnings Date | May 30, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
| Current Share Class | n/a |
| Shares Outstanding | n/a |
| Shares Change (YoY) | +10.51% |
| Shares Change (QoQ) | -0.10% |
| Owned by Insiders (%) | n/a |
| Owned by Institutions (%) | n/a |
| Float | 15.19M |
Valuation Ratios
The trailing PE ratio is 37.10.
| PE Ratio | 37.10 |
| Forward PE | n/a |
| PS Ratio | 4.56 |
| PB Ratio | 3.36 |
| P/TBV Ratio | 3.41 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | 36.39 |
| EV / Sales | 4.48 |
| EV / EBITDA | 40.29 |
| EV / EBIT | 47.30 |
| EV / FCF | n/a |
Financial Position
| Current Ratio | n/a |
| Quick Ratio | n/a |
| Debt / Equity | 0.13 |
| Debt / EBITDA | 1.65 |
| Debt / FCF | n/a |
| Interest Coverage | 6.04 |
Financial Efficiency
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | n/a |
| Return on Invested Capital (ROIC) | 4.02% |
| Return on Capital Employed (ROCE) | n/a |
| Revenue Per Employee | 10.35M |
| Profits Per Employee | 1.27M |
| Employee Count | 871 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -22.96% in the last 52 weeks.
| Beta (5Y) | n/a |
| 52-Week Price Change | -22.96% |
| 50-Day Moving Average | 904.58 |
| 200-Day Moving Average | 1,332.70 |
| Relative Strength Index (RSI) | 48.08 |
| Average Volume (20 Days) | 11,515 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Orchid Pharma had revenue of INR 9.02 billion and earned 1.11 billion in profits. Earnings per share was 21.87.
| Revenue | 9.02B |
| Gross Profit | 3.48B |
| Operating Income | 851.15M |
| Pretax Income | 1.08B |
| Net Income | 1.11B |
| EBITDA | 996.32M |
| EBIT | 851.15M |
| Earnings Per Share (EPS) | 21.87 |
Balance Sheet
The company has 2.44 billion in cash and 1.65 billion in debt, giving a net cash position of 789.49 million.
| Cash & Cash Equivalents | 2.44B |
| Total Debt | 1.65B |
| Net Cash | 789.49M |
| Net Cash Per Share | n/a |
| Equity (Book Value) | 12.24B |
| Book Value Per Share | 241.38 |
| Working Capital | n/a |
Cash Flow
| Operating Cash Flow | n/a |
| Capital Expenditures | n/a |
| Free Cash Flow | n/a |
| FCF Per Share | n/a |
Margins
Gross margin is 38.66%, with operating and profit margins of 9.44% and 12.30%.
| Gross Margin | 38.66% |
| Operating Margin | 9.44% |
| Pretax Margin | 11.94% |
| Profit Margin | 12.30% |
| EBITDA Margin | 11.05% |
| EBIT Margin | 9.44% |
| FCF Margin | n/a |
Dividends & Yields
Orchid Pharma does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -10.51% |
| Shareholder Yield | -10.51% |
| Earnings Yield | 2.70% |
| FCF Yield | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | n/a |